A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
Status:
Completed
Trial end date:
2018-05-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination
with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or
GT2 or GT3 chronic hepatitis C (CHC) infection.